D. E. Shaw & Co., Inc. Tango Therapeutics, Inc. Call Options Transaction History
D. E. Shaw & Co., Inc.
- $107 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding TNGX
# of Institutions
123Shares Held
91.7MCall Options Held
3.1KPut Options Held
1.5K-
Trv Gp Iv, LLC Boston, MA16.9MShares$52.6 Million80.09% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA13.3MShares$41.6 Million4.45% of portfolio
-
Boxer Capital, LLC San Diego, CA8.2MShares$25.6 Million3.35% of portfolio
-
Nextech Invest Ag5.53MShares$17.3 Million6.95% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD5.02MShares$15.7 Million0.02% of portfolio
About Tango Therapeutics, Inc.
- Ticker TNGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 88,067,296
- Market Cap $275M
- Description
- Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops...